Alumis Inc. Common Stock

Alumis Inc. Common Stock (ALMS) Market Cap

Alumis Inc. Common Stock has a market capitalization of $2.35B.

Price: $19.06

β–Ό -1.33 (-6.52%)

Market Cap: 2.35B

NASDAQ Β· time unavailable

CEO: Martin Babler

Sector: Healthcare

Industry: Biotechnology

IPO Date: 2021-02-22

Website: https://www.alumis.com

Alumis Inc. Common Stock (ALMS) - Company Information

Market Cap: 2.35B|Sector: Healthcare

Company Profile

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.

Analyst Sentiment

92%
Strong Buy

From 11 Active Polls

1Y Forecast: $39.33

β–² +106.3% Potential Upside

Consensus Target Metrics

Low Bound

$25

Median

$39

High Bound

$51

Average

$39

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$39.33
β–² +106.35% Upside
Low Target
$25.00
31% Risk
Median Target
$39.00
105% Mid
High Target
$51.00
168% Max
Consensus
Buy
7 / 8 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

πŸ“Š Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)2,3532,7551,022415229333422574682
Enterprise Value ($M)2,3242,727969388116237284392559
Price to Earnings Ratio (P/E)-10.04-7.40-2.75-0.940.97-0.84-1.11-1.54-3.02
Price/Earnings-to-Growth Ratio (PEG)β€”β€”β€”β€”β€”β€”β€”β€”β€”
Price to Sales Ratio (P/S)280.011582.35529.78201.0686.0619.17β€”β€”β€”
Price to Book Ratio (P/B)4.204.863.391.080.471.981.621.65-1.55
Price to Free Cash Flow Ratio (P/FCF)-6.24-31.58-14.21-3.75-2.14-4.15-5.62-6.79-12.94
Enterprise Value to Sales (EV/Sales)β€”1566.14502.43187.7743.6813.61β€”β€”β€”
Enterprise Value to EBITDA (EV/EBITDA)-5.44-27.95-10.14-3.39-0.97-2.35-3.02-4.01-10.09
Debt to Equity Ratio0.070.060.120.100.080.190.120.09-0.07

⚑ ALMS Growth Runway Model

Standard long term linear growth fade

Multi-Stage Discounted Cash Flow Sandbox

Market Price$19.06
Intrinsic Value$0.16
Market Alignment
Overvalued by 99.2%relative to calculated intrinsic value
9.00%
Exp: 0%0%
i

Growth runway slowdown

This value provides a time window for the growth rate to decline beyond Stage 1 toward the terminal rate. Longer windows are most useful for companies with high growth starting conditions or strong competitive advantages. This option stretches out the growth rate slowdown across 5, 10, or 15-year steps. A high-growth starting condition (exceeding a 25% initial growth rate) automatically applies a curve decay to simulate realistic, rapid market saturation.
i

Terminal growth rate

With long-term inflation between 3-5%, revenue must grow by that baseline to maintain flat real-world market share. This value sets the permanent terminal growth rate to factor into the valuation beyond the growth slowdown runway toward maturity.

3-Stage Financial Runway Horizon

🧠 Perpetuity Horizon Engine (Stage 3: Post-2035)

Terminal FCF Base$0.03B
Perpetuity TV Value$0.54B
Discounted TV (PV)$0.23B
TV Weighting %57.9%
⚠️
Financial Model Disclaimer & Risk Disclosure: This interactive scenario simulator is an educational sandbox provided strictly for informational and analytical research purposes. Core historical financial statements and consensus estimates are sourced directly via Financial Modeling Prep (FMP). All downstream outputs are entirely deterministic, hypothetical projections generated by combining automated mathematical formulas (including linear interpolation and Gaussian bell-curve decay models) with user-selected variables and third-party financial data inputs. Users assume all liability for trading decisions executed based on these sandbox calculations.

πŸ“˜ Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

πŸ“˜ ALUMIS INC (ALMS) β€” Investment Overview

🧩 Business Model Overview

ALUMIS INC operates in the aluminum value chain as a manufacturer and processor of aluminum products for industrial and end-market customers. The core β€œhow it works” is a production-to-customer workflow: incoming aluminum input (and related processing inputs) is transformed through proprietary processing steps into customer-specified products, followed by sales into qualified customer programs.

Because industrial customers require consistent quality, reliable supply, and repeatable processing performance, the business model naturally emphasizes product qualification, adherence to specifications, and ongoing production executionβ€”factors that increase customer stickiness after initial onboarding.

πŸ’° Revenue Streams & Monetisation Model

Revenue is primarily generated through the sale of aluminum products on contractual and purchase-order arrangements. Monetisation is driven by (1) volume throughput and (2) the net pricing achievable for processed products versus input costs.

Margin structure typically reflects:

  • Product mix and processing depth: higher-value downstream processing generally supports better gross margin profiles.
  • Manufacturing utilization: fixed costs are spread over higher volumes when production runs consistently.
  • Input-cost pass-through: where pricing mechanisms mitigate aluminum and energy/input volatility, earnings quality improves.

🧠 Competitive Advantages & Market Positioning

Competitive moat (structural): customer qualification switching costs combined with execution reliability in a tightly specified manufacturing environment.

Once a customer’s engineering, quality, and sourcing teams qualify materials and manufacturing processes, switching suppliers is costly and time-consuming. Competitors can sell similar material only after meeting qualification requirements, maintaining consistent quality, and supporting schedule reliabilityβ€”creating a practical barrier beyond simple pricing.

  • ALUMIS positioning: focus on delivering processed aluminum products with production consistency and qualification-driven customer stickiness.
  • Competitor set: Novelis, Constellium, and Hydro (among the broader aluminum processing ecosystem).

Contrast vs. rivals: Novelis, Constellium, and Hydro tend to compete across wide aluminum processing categories and end markets, leveraging scale and product breadth. The practical differentiation for ALUMIS is less about absolute scale and more about qualification-driven customer retention, manufacturing execution, and the ability to sustain repeatable quality at the product level customers require.

πŸš€ Multi-Year Growth Drivers

Over a 5–10 year horizon, growth prospects for a specialized aluminum processor are typically supported by:

  • Ongoing lightweighting demand: aluminum substitutes for heavier materials in transportation and industrial applications where weight, corrosion resistance, and lifecycle performance matter.
  • End-market diversification: spreading exposure across multiple industrial demand streams reduces dependence on a single cycle.
  • Qualification β€œpull-through”: once programs are established, follow-on orders can extend customer relationships, supporting volume stability.
  • Process optimization: improvements in yield, scrap reduction, and throughput can drive margin expansion without requiring broad price increases.

TAM expansion is fundamentally tied to aluminum’s share gains in weight- and performance-sensitive applications and to the incremental complexity customers place on sourcing (quality, schedule certainty, and specification compliance).

⚠ Risk Factors to Monitor

  • Input-price and spread volatility: aluminum and related input costs can pressure margins if pricing mechanisms do not sufficiently offset volatility.
  • Capacity utilization risk: industrial manufacturing economics can deteriorate when demand weakens and fixed-cost absorption falls.
  • Customer concentration and program timing: changes in customer sourcing strategies, product redesigns, or program delays can affect volumes.
  • Execution and quality risk: failure to meet specification or delivery reliability can force requalification cycles and increase churn risk.
  • Regulatory and environmental compliance: manufacturing compliance costs and evolving environmental requirements can affect operating economics.

πŸ“Š Valuation & Market View

Industrial and materials-linked manufacturers are commonly valued on EV/EBITDA, enterprise value relative to earnings power, and cash flow durability, with sentiment often influenced by expectations for manufacturing utilization and input-cost pass-through.

Key valuation drivers typically include:

  • Normalized margins: sustained ability to convert throughput and mix into resilient gross profit.
  • Operating leverage: evidence that earnings improve with volume rather than merely through price cycles.
  • Working-capital discipline: inventory and receivables management that supports free cash flow through cycles.
  • Program longevity: visibility into customer qualification-driven order flow.

πŸ” Investment Takeaway

ALUMIS INC’s long-term case rests on qualification-driven switching costs and the ability to sustain repeatable manufacturing execution in a specification-heavy aluminum processing environment. While results remain exposed to the industrial cycle and input-cost volatility, the strongest structural support for an evergreen thesis is the practical difficulty competitors face in displacing qualified suppliers once customer programs are established.


⚠ AI-generated β€” informational only. Validate using filings before investing.

πŸ“° Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for ALMS.

fool.comβ€’2026-05-24

This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter

This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors.

fool.comβ€’2026-05-17

Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter

Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.

fool.comβ€’2026-05-15

Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back

Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases using allosteric TYK2 inhibitors.

globenewswire.comβ€’2026-05-14

Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements

– Late-breaking oral presentation of Phase 3 envudeucitinib data in moderate-to-severe plaque psoriasis (PsO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting demonstrating early and robust improvements in skin clearance, quality of life, and symptoms –

fool.comβ€’2026-05-10

Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug

Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology.

globenewswire.comβ€’2026-03-28

Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis

Envudeucitinib late-breaking data at AAD: early and robust improvements in skin clearance, quality of life and psoriasis symptoms in two Phase 3 trials

seekingalpha.comβ€’2026-03-25

Alumis: Oral Psoriasis Med Can Win Approval, Challenge Big Pharma In Major Markets

Alumis Inc. is upgraded to Buy, reversing a prior Sell, based on strong Phase 3 envudeucitinib psoriasis data and pipeline potential. Envudeucitinib demonstrated efficacy comparable to JNJ's newly approved Icotyde, with 74% PASI 75 and 59% sPGA 0/1 at week 16. ALMS targets NDA submission for envudeucitinib in 2H 2026, with additional data in psoriatic arthritis and SLE expected in 2026.

globenewswire.comβ€’2026-03-19

Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements

– Positive Phase 3 topline results demonstrating envudeucitinib's leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque psoriasis (PsO) –

globenewswire.comβ€’2026-03-18

Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting

– Phase 3 data presentation highlighting results from the ONWARD1 and ONWARD2 clinical trials of envudeucitinib – – Phase 2 STRIDEΒ e-poster presentation to describe disease biomarker activity of envudeucitinib – – Alumis to host investor webcast on Sunday, March 29, 2026, at 5:00 pm MDT / 7:00 pm EDT – SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that results from its Phase 3 ONWARD program evaluating envudeucitinib, a next-generation oral tyrosine kinase 2 (TYK2) inhibitor for moderate-to-severe plaque psoriasis, have been accepted for a late-breaking oral presentation, and that a new biomarker analysis from the Phase 2 STRIDE trial of envudeucitinib has been accepted as an e-poster at the 2026 American Academy of Dermatology (AAD) Annual Meeting, taking place March 27–31, 2026, in Denver, Colorado.

globenewswire.comβ€’2026-03-02

Alumis to Present at the Leerink Partners Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Monday, March 9, 2026, at 10:40 a.m. ET.

defenseworld.netβ€’2026-02-28

AXQ Capital LP Invests $78,000 in Alumis Inc. $ALMS

AXQ Capital LP bought a new stake in Alumis Inc. (NASDAQ: ALMS) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 19,452 shares of the company's stock, valued at approximately $78,000. Several other hedge funds and other institutional investors

defenseworld.netβ€’2026-02-16

Credit Industriel ET Commercial Sells 140,000 Shares of Alumis Inc. $ALMS

Credit Industriel ET Commercial lessened its holdings in shares of Alumis Inc. (NASDAQ: ALMS) by 36.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 247,002 shares of the company's stock after selling 140,000 shares during the quarter. Credit

globenewswire.comβ€’2026-02-05

Alumis to Participate in Upcoming February Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will participate in the following investor conferences:

fool.comβ€’2026-02-03

Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.

This clinical-stage biotech develops therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition.

defenseworld.netβ€’2026-01-30

Alumis Inc. (NASDAQ:ALMS) Short Interest Up 93.1% in January

Alumis Inc. (NASDAQ: ALMS - Get Free Report) was the target of a significant growth in short interest in the month of January. As of January 15th, there was short interest totaling 8,672,088 shares, a growth of 93.1% from the December 31st total of 4,492,125 shares. Based on an average daily trading volume, of 10,417,053 shares,

πŸ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"ALMS reported Q1’26 revenue of $1.74M and net income of -$93.1M (EPS -$0.74). On a QoQ basis, revenue fell from $1.93M in Q4’25 to $1.74M in Q1’26 (-9.8% QoQ). On a YoY basis, revenue was down sharply versus $17.39M in Q1’25 (-90.0% YoY). Net income remained deeply loss-making: -$93.1M in Q1’26 versus -$92.9M in Q4’25 (about flat QoQ, +0.1%) and versus -$98.96M in Q1’25 (improvement of +5.9% YoY). Profitability remains weak, with net margin at -53.4% in Q1’26; operating margin deteriorated versus Q4’25 (-43.8%) to -56.5%, consistent with margin contraction driven by very high R&D. Cash flow is pressured but largely offset by financing and investment flows. Operating cash flow was -$87.1M, while investing cash flow was -$285.7M, reflecting heavy purchases of investments. Despite this, financing cash flow was +$347.0M, driven by common stock issued (dilution). Balance sheet liquidity is still strong: cash & short-term investments were $522.9M at 2026-03-31, with net cash (net debt -$28.2M). No dividends were paid and there were no buybacks. From a shareholder returns perspective, the stock shows exceptional momentum (1Y change +392.9%), which should materially boost total return despite ongoing operating losses and negative free cash flow."

Revenue Growth

Neutral

Revenue declined -9.8% QoQ (from $1.93M to $1.74M) and -90.0% YoY (from $17.39M). Trajectory is sharply down.

Profitability

Neutral

Net income improved slightly YoY (-$98.96M to -$93.05M, +5.9% less loss) but QoQ was essentially flat. Margins remain highly negative: net margin -53.4% in Q1’26 vs -48.2% in Q4’25 (contraction).

Cash Flow Quality

Neutral

Operating cash flow was -$87.1M and free cash flow -$87.2M. No dividends/buybacks; financing via dilution (+$323.8M stock issued) helped offset cash burn.

Leverage & Balance Sheet

Positive

Liquidity remains strong with cash & short-term investments of $522.9M. Net debt is negative (net cash -$28.2M). Equity is positive though below recent highs due to heavy retained losses.

Shareholder Returns

Strong

Strong market momentum: 1Y price change +392.9% (no dividend). Total shareholder return likely dominated by capital appreciation.

Analyst Sentiment & Valuation

Fair

Price targets imply upside (consensus $38.44 vs $24.99 current) despite extreme losses and high valuation multiples relative to revenue/earnings.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

πŸ“‹ Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for ALMS.

SEC EDGAR Live Feed
Loading financial data and tables...
πŸ“

SEC Filings (ALMS)

Β© 2026 Stock Market Info β€” Alumis Inc. Common Stock (ALMS) Financial Profile